Business
PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023
PDS Biotech prepares to advance PDS0101 into a Phase 3 registrational clinical trial – VERSATILE-003 – in HPV16-positive recurrent and/or metastatic head and
About this update from Pds Biotechnology Corporation
[{"type":"text","content":"PDS Biotech prepares to advance PDS0101 into a Phase 3 registrational clinical trial – VERSATILE-003 – in HPV16-positive recurrent and/or metastatic head and neck cancer in 2023\nFLORHAM PARK, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced its support for Oral, Head & Neck Cancer Awareness Month in April and Oral, Head & Neck Cancer Awareness Week, April 16-22, both of which are organized by the Head & Neck Cancer Alliance (HCNA). PDS Biotech recognizes the important role and dedication of patient organizations, such as the HCNA and the U.K.-based Swallows Head & Neck Cancer Support Group (The Swallows) in not only raising awareness of oral, head and neck cancer, but also in providing advice, information and education to those impacted by the disease. PDS Biotech recently announced it is planning to initiate a randomized, controlled Phase 3 trial of the company’s lead clinical candidate, PDS0101, in combination with KEYTRUDA® (pembrolizumab) for the potential treatment of human papillomavirus (HPV)16-positive head and neck cancer. A growing number of head and neck cancers are caused by HPV1,2 and 90% of HPV-associated head and neck cancers in the US are reported to be caused by HPV16, as reported in a study published in the Journal of Clinical Medicine.3 “Head and neck cancer is among the most difficult-to-treat cancers, often leading to severe disfigurement and, in the worst cases, death,” said Dr. Frank Bedu-Addo, PDS Biotech CEO. “The tireless efforts of HCNA and The Swallows have been instrumental in increasing awareness of this devastating disease, including greater patient screening, access, and information about its association with HPV. We are proud to join these organizations during the month of April to celebrate the progress made while acknowledging that more is needed. To address this unmet need, PDS Biotech is advancing PDS0101 to a Phase 3 clinical trial for HPV16-positive recurrent and/or metastatic head and neck cancer, with the hope that we may soon be able to improve the lives of patients and their caregivers.” “The mission of the Head and Neck Cancer Alliance is to advance the prevention, detection, treatment and rehabilitation of ...